These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Interaction between fosamprenavir, with and without ritonavir, and nevirapine in human immunodeficiency virus-infected subjects. DeJesus E; Piliero PJ; Summers K; Wire MB; Stein DS; Masterman A; Lou Y; Min SS; Shelton MJ Antimicrob Agents Chemother; 2006 Sep; 50(9):3157-9. PubMed ID: 16940117 [TBL] [Abstract][Full Text] [Related]
5. Protease inhibitor plasma concentrations in HIV antiretroviral therapy. Justesen US Dan Med Bull; 2008 Nov; 55(4):165-85. PubMed ID: 19232158 [TBL] [Abstract][Full Text] [Related]
6. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy. Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694 [TBL] [Abstract][Full Text] [Related]
7. Current clinical treatments of AIDS. Murphy EM; Jimenez HR; Smith SM Adv Pharmacol; 2008; 56():27-73. PubMed ID: 18086408 [No Abstract] [Full Text] [Related]
8. Interactions among drugs for HIV and opportunistic infections. Piscitelli SC; Gallicano KD N Engl J Med; 2001 Mar; 344(13):984-96. PubMed ID: 11274626 [No Abstract] [Full Text] [Related]
9. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Boffito M; Acosta E; Burger D; Fletcher CV; Flexner C; Garaffo R; Gatti G; Kurowski M; Perno CF; Peytavin G; Regazzi M; Back D Antivir Ther; 2005; 10(4):469-77. PubMed ID: 16038472 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Weiss J; Weis N; Ketabi-Kiyanvash N; Storch CH; Haefeli WE Eur J Pharmacol; 2008 Jan; 579(1-3):104-9. PubMed ID: 18037401 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. Holguín A; Ramirez de Arellano E; Rivas P; Soriano V AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277 [TBL] [Abstract][Full Text] [Related]
12. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement? Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R; Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650 [TBL] [Abstract][Full Text] [Related]
13. Understanding transmitted HIV resistance through the experience in the USA. Taiwo B Int J Infect Dis; 2009 Sep; 13(5):552-9. PubMed ID: 19136289 [TBL] [Abstract][Full Text] [Related]
14. Transmitted multidrug resistant HIV-1: new and investigational therapeutic approaches. Shet A; Markowitz M Curr Opin Investig Drugs; 2006 Aug; 7(8):709-20. PubMed ID: 16955682 [TBL] [Abstract][Full Text] [Related]
15. Primary drug resistance in antiretroviral-naïve injection drug users. Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493 [TBL] [Abstract][Full Text] [Related]
16. Drug interactions, toxicities, dosages: trials and tribulations and cocktails. Crit Path AIDS Proj; 1998; (No 33):9-17. PubMed ID: 11366377 [TBL] [Abstract][Full Text] [Related]
18. Are men and women really different? Res Initiat Treat Action; 1998 Dec; 4(7):13. PubMed ID: 11366080 [TBL] [Abstract][Full Text] [Related]
19. Anti-HIV drugs. De Clercq E Verh K Acad Geneeskd Belg; 2007; 69(2):81-104. PubMed ID: 17550060 [TBL] [Abstract][Full Text] [Related]
20. Current concepts in antiretroviral therapy failure. del Rio C Top HIV Med; 2006; 14(3):102-6. PubMed ID: 16946454 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]